Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.35 |
| ▸ | DRD2 | P14416 | 7/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080767 | 1.00 | DRD3 (0.35) | DRD3DRD2DRD4ARALDH1A1 | |
| SCHEMBL5212144 | 0.85 | — | — | |
| SCHEMBL4684582 | 0.85 | — | — | |
| SCHEMBL14102222 | 0.81 | GAA (0.36) | DRD3DRD2DRD4ALDH1A1CYP1A2 | |
| SCHEMBL13647108 | 0.68 | — | — | |
| SCHEMBL17722879 | 0.64 | — | — | |
| SCHEMBL3841884 | 0.64 | NAAA (0.32) | — | |
| SCHEMBL18959038 | 0.63 | LTA4H (0.40) | DRD3DRD2DRD4ALDH1A1CYP1A2 | |
| SCHEMBL18959040 | 0.63 | LTA4H (0.40) | DRD3DRD2DRD4ALDH1A1CYP1A2 | |
| SCHEMBL9801705 | 0.63 | LTA4H (0.40) | DRD3DRD2DRD4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753763-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Pfizer Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116027-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LIMTED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | DRD3 2/4885DRD2 1/4885DRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.